Objectives: Lack of small-sized homografts is a major obstacle to reconstruct the right ventricular outflow tract(RVOT) in early infancy. We hypothesized that femoral vein homograft may be a substitute because of suitable size for small infants and valve function. The aim of this study is to assess the clinical outcome of a cryopreserved femoral vein homograft as a valved conduit in the pulmonary position. Methods: From July 2007 to July 2009, 10 patients underwent placement of cryopreserved femoral vein homografts for right ventricle to pulmonary artery connection. Their median age at surgery was 2.6 months (range, 4 days ~ 8.2 months). Median body weight was 3.9 (range, 3.1 ~ 8) kg. Six patients underwent biventricular repair including Norwood-Rastelli operation for aortic atresia (n=3); Rastelli-type operation for pulmonary atersia/VSD with major aortopulmonary collaterals (n=1), without collaterals (n=1), and truncus arteriosus(n=1). Four patients underwent palliative RVOT reconstruction for pulmonary atresia/VSD with major aortopulmonary collaterals (n=3), and pulmonary atreisa/DORV (n=1). Associated anomalies were CATCH 22 in 4 patients and multiple facial anomaly in 1 patient. The diameter of the homograft was less than 12mm in all patients (median 9.5mm). Results: There was no early death. Median follow-up period was 9.2 (range, 2.0 ~ 22.7) months. One patient died suddenly 7 months after Norwood-Rastelli operation even though the homograft function had been good until the last visit. Among the six patients who had undergone biventricular repair, two showed graft dysfunction. One of them underwent conduit replacement 10 months after initial operation. Two of the four patients palliated underwent subsequent total correction with conduit replacement, 3.5 and 9 months after initial operation, respectively. Conclusions: Although the population of this study is small, cryopreserved femoral vein valved homograft can be used safely for RVOT reconstruction in small infants. The graft may facilitate early total correction and promote the growth of the native pulmonary artery for palliation. However, durability must be determined with longer follow-up.